On September 29, 2023, Brandon Romanek resigned as CEO of THC Therapeutics, Inc., and Scott Cox was appointed as Interim CEO of the Company. Mr. Cox, age 51, has over 20 years of experience in the management and operations of public and private companies. Since November 2019, Mr. Cox has been the CEO of Verde Bio Holdings, Inc. and he has been a member of its Board of Directors since January 2020.

Mr. Cox served as the President and COO of NewBridge Global Ventures, Inc. from October 2017 to September 2018, where he led a transition into the legal cannabis space and successful reverse merger with a family-owned consortium of companies. Since October 2015, Mr. Cox has served as a Principal in Basin Capital, Inc., a private family office focused on the acquisition and divestiture of oil and gas properties and various entrepreneurial ventures. Prior to Basin Capital, from July 2013 to October 2015, Mr. Cox served as Vice President of Land for Breitling Energy Corporation, where he was instrumental in acquiring over $20 million in producing and non-producing oil and gas properties.

Prior to that he served as Director of Operations for Frontier Oilfield Services, Inc., from September 2012, where he helped lead a public company acquisition and roll-up of two privately owned oilfield service companies. In consideration of Mr. Cox?s appointment, the Company issued Mr. Cox 600,000 shares of Series A Preferred Stock (the ?Shares?) valued at $0.30/share, which issuance constituted a change of control of the Company as each share of Series A Preferred Stock is entitled to 100 votes and converts into 100 shares of Company common stock. The Shares were issued to Mr. Cox in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder, as there was no general solicitation, and the transaction did not involve a public offering.